8-K: Corbus CRB-701 Shows Strong Efficacy in Cancer Study

Corbus Pharmaceuticals announced positive Phase 1/2 clinical data for CRB-701 in HNSCC, cervical, and urothelial cancers, demonstrating robust responses and a favorable safety profile.

Summary

• Presented Phase 1/2 clinical study data for CRB-701 (SYS6002) at ESMO25 on October 19, 2025.
• Data as of September 1, 2025, included 167 patients, with 122 evaluable for efficacy, who were heavily pretreated with a median of 3 prior lines of therapy.
• CRB-701 demonstrated objective response rates (ORR) of 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), and 55.6% in metastatic urothelial cancer (mUC, n=9) at the 3.6 mg/kg dose.
• The drug showed a favorable safety and tolerability profile, with no dose-limiting toxicities (DLTs) during dose escalation and a low discontinuation rate of 6.0%.
• Grade 3 treatment-related adverse events were reported in 18.0% of patients, with no Grade 4 or 5 events.
• Peripheral neuropathy was notably low at 8.4% (all Grade 1 or 2).
• Clinical responses were observed irrespective of Nectin-4 expression, HPV status (HNSCC), or PD(L)-1 status (HNSCC).

Sentiment

Score: 8

Explanation: The clinical data for CRB-701 shows strong efficacy across multiple difficult-to-treat cancers with a significantly improved safety profile compared to existing Nectin-4 ADCs. The planned progression to registrational studies and Fast Track designations are highly positive indicators, despite the decision to not pursue mUC as a primary indication.

Positives

• Robust objective response rates (ORR) at 3.6 mg/kg: 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in mUC.
• Favorable safety and tolerability profile, with no dose-limiting toxicities during dose escalation.
• Low rate of peripheral neuropathy at 8.4% (all Grade 1 or 2), which is significantly lower than comparable Nectin-4 ADCs like PADCEV (48%).
• Low discontinuation rate related to CRB-701 at 6.0%.
• Responses observed across various biomarker statuses (Nectin-4, HPV, PD(L)-1), indicating broad applicability.
• CRB-701 has received two FDA Fast Track designations for HNSCC and cervical cancer.
• Company plans to initiate registrational studies by mid-2026.

Negatives

• Grade 3 treatment-related adverse events were reported in 18.0% of patients.
• Some responses were unconfirmed and ongoing as of the September 1, 2025 data cut.
• The company is not currently pursuing mUC as a stand-alone indication due to the competitive landscape dominated by Keytruda + PADCEV.

Risks

• Future clinical trials of CRB-701 may not reproduce, validate, or otherwise confirm the observations described.
• Actual results, performance, or achievements may be materially different from forward-looking statements due to known and unknown risks, uncertainties, and other factors on operations, clinical development plans, and timelines.

Future Outlook

The company plans to meet with the FDA in 2025 to review the CRB-701 data and expects to initiate registrational studies by mid-2026. Updates on the regulatory pathway are anticipated in Q1 2026. Combination data for CRB-701 with pembrolizumab is expected mid-2026. Additionally, CRB-913 and CRB-601 have upcoming milestones in Q4 2025 and mid-2026.

Management Comments

• "I'm immensely gratified and encouraged by the pace of enrollment and response rate seen in the study to date. It comes at a time when there is a stark unmet need for the many HNSCC patients not responding to front-line therapy. The emerging CRB-701 safety and efficacy data is showing differentiation from other experimental agents in HNSCC, and we are looking forward to continuing the development of this novel ADC." Dominic Smethurst, Chief Medical Officer.
• "Although data is still early with CRB-701, the lower systemic toxicity burden we are seeing compared with other ADCs or cytotoxics is quite exciting along with this preliminary efficacy signal. I look forward to seeing further data regarding this exciting compound." Dr. Ari Rosenberg, Principal Investigator.
• "We look forward to discussions with regulatory authorities and other potential stakeholders to determine the fastest and most efficient path to market. We aim to provide those updates in Q1 2026." Yuval Cohen, PhD, Chief Executive Officer.

Industry Context

CRB-701 is positioned as a next-generation Nectin-4 targeting ADC, aiming to differentiate itself from existing treatments like PADCEV by focusing on non-mUC tumors (HNSCC, cervical cancer) and demonstrating a more favorable safety profile, particularly regarding peripheral neuropathy. The company acknowledges the competitive landscape in mUC, where Keytruda + PADCEV dominate. The positive results in HNSCC and cervical cancer address significant unmet needs in heavily pretreated patient populations, potentially offering a new standard of care.

Comparison to Industry Standards

• CRB-701's peripheral neuropathy rate of 8.4% (all Grade 1 or 2) is significantly lower than PADCEV's 48% and BT8009's 36%.
• CRB-701's Grade 3 AE rate of 35.5% (at 3.6mg/kg) is lower than PADCEV's 62.5% and BT8009's 53%.
• In HNSCC, CRB-701's ORR of 47.6% (at 3.6mg/kg) compares favorably to Petosemtamab's 36% and PADCEV's 23.9% in 2L HNSCC.
• In cervical cancer, CRB-701's ORR of 37.5% (at 3.6mg/kg) is substantially higher than Tivdak's 17.8% in 2L.
• In mUC, CRB-701's ORR of 55.6% (at 3.6mg/kg) is higher than PADCEV's 44% in 2nd line, though Corbus is not pursuing mUC as a stand-alone indication.

Stakeholder Impact

• Shareholders: Positive clinical data and clear path to registrational studies could increase investor confidence and share value.
• Patients: CRB-701 offers a potentially more effective and better-tolerated treatment option for patients with HNSCC and cervical cancer, addressing significant unmet medical needs.
• Healthcare Providers: The favorable safety profile, particularly reduced peripheral neuropathy, could make CRB-701 a preferred treatment option.

Next Steps

• Meet with the FDA in 2025 to review CRB-701 data.
• Provide updates on the regulatory pathway for CRB-701 in Q1 2026.
• Initiate CRB-701 monotherapy Phase 2/3 registrational studies by mid-2026.
• Release CRB-701 + pembrolizumab combination data by mid-2026.
• Complete Phase 1 SAD/MAD for CRB-913 in Q4 2025.
• Start Phase 1B study for CRB-913 in Q4 2025.
• Complete Phase 1 dose escalation for CRB-601 in Q4 2025.

Key Dates

Recommendation

The robust efficacy data for CRB-701 in HNSCC and cervical cancer, coupled with a significantly improved safety profile compared to current Nectin-4 ADCs, positions it as a potential best-in-class therapy. The clear regulatory pathway with planned registrational studies by mid-2026 and existing Fast Track designations indicate strong development momentum. While the decision to not pursue mUC as a primary indication is noted, the focus on areas of high unmet need where CRB-701 shows differentiation is strategically sound. The positive clinical results are highly likely to drive significant shareholder value.

Keywords

CRB-701, Nectin-4 ADC, HNSCC, Cervical Cancer, Urothelial Cancer, Oncology, Clinical Trial, Phase 1/2, ESMO25, Antibody-Drug Conjugate, Biotechnology, Cancer Treatment, Corbus Pharmaceuticals